vimarsana.com

Page 8 - புதியது யார்க் இதயம் சங்கம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Mavacamten for hypertrophic obstructive cardiomyopathy

Mavacamten for hypertrophic obstructive cardiomyopathy
thelancet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thelancet.com Daily Mail and Mail on Sunday newspapers.

FDA Clears Vericiguat to Treat Heart Failure Following Hospitalization

FDA Clears Vericiguat to Treat Heart Failure Following Hospitalization Verquvo is the first soluble guanylate cyclase stimulator drug cleared by FDA to treat heart failure January 25, 2021 The U.S. Food and Drug Administration (FDA) approved Merck s Verquvo (vericiguat). It is the first treatment for chronic heart failure approved specifically for patients following a hospitalization for heart failure or need for outpatient IV diuretics.  The drug is supposed to reduce the risk of cardiovascular death and heart failure hospitalization in indicated patients  with symptomatic chronic heart failure and ejection fraction less than 45%. Vericiguat is a soluble guanylate cyclase (sGC) stimulator, and is the first drug in this class ro be cleared by the FDA for heart failure. 

Integrating modern and traditional medicine: Facts and figures

Integrating modern and traditional medicine: Facts and figures Artemisinin, which is extracted from Artemisia annua or Chinese sweet wormwood, is the basis for the most effective malaria drugs the world has ever seen. Western researchers first became aware of the compound in the 1980s, though it had long been used in China to treat malaria. But it wasn t until 2004 that the WHO endorsed its use worldwide. Much of this delay was because of the skepticism about the drug, and different research groups spent years validating the claims of Chinese traditional healers. Artemisinin is proving useful against other diseases too and has been shown to have great potential in treating cancers and schistosomiasis.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.